Compare BOXL & AZTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BOXL | AZTR |
|---|---|---|
| Founded | 1985 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3M | 3.5M |
| IPO Year | 2015 | 2023 |
| Metric | BOXL | AZTR |
|---|---|---|
| Price | $0.79 | $0.22 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 82.7K | ★ 439.7K |
| Earning Date | 04-16-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 5.06 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $25,743,612.00 | N/A |
| Revenue This Year | $2.70 | N/A |
| Revenue Next Year | $5.00 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 26.37 | N/A |
| 52 Week Low | $0.50 | $0.10 |
| 52 Week High | $10.15 | $1.40 |
| Indicator | BOXL | AZTR |
|---|---|---|
| Relative Strength Index (RSI) | 37.74 | 50.71 |
| Support Level | $0.71 | $0.21 |
| Resistance Level | $0.97 | $0.23 |
| Average True Range (ATR) | 0.07 | 0.02 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 32.75 | 71.16 |
Boxlight Corp is a technology company that develops, sells, and services interactive solutions predominantly for the education market but also for the corporate and government sectors. The company currently designs, produces, and distributes interactive technologies, including interactive and non-interactive flat panel displays, LED video walls, media players, classroom audio and campus communication, cameras, and other peripherals for the education market and non-interactive solutions, including flat-panels, LED video walls, and digital signage for the enterprise market. It has three reportable segments - Europe, Middle East and Africa (EMEA), and North and Central America (Americas). The majority of revenue is derived from the sale of education technology products in the EMEA segment.
Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products. Its discovery platform is screened for naturally occurring bacterial cells with beneficial effects. These microbes are then genomically sequenced and engineered to make cellular therapies, recombinant therapeutic proteins, peptides, and small molecules for the precision treatment of dermatology diseases. The company's product candidates include ATR-12, for treating the orphan disease and Netherton syndrome; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash; and ATR-01, a potential treatment for ichthyosis vulgaris, a chronic, abnormally dry, scaly skin disease.